Parkinson disease: an update.

Parkinson disease is a progressive neurologic disorder afflicting approximately 1 percent of Americans older than 60 years. The cardinal features of Parkinson disease are bradykinesia, rigidity, tremor, and postural instability. There are a number of neurologic conditions that mimic the disease, making it difficult to diagnose in its early stages. Physicians who rarely diagnose Parkinson disease should refer patients suspected of having it to physicians with more experience in making the diagnosis, and should periodically reevaluate the accuracy of the diagnosis. Treatment is effective in reducing motor impairment and disability, and should be started when a patient begins to experience functional impairment. The combination of carbidopa and levodopa is the most effective treatment, but dopamine agonists and monoamine oxidase-B inhibitors are also effective, and are less likely to cause dyskinesias. For patients taking carbidopa/levodopa who have motor complications, adjunctive therapy with a dopamine agonist, a monoamine oxidase-B inhibitor, or a catechol O-methyltransferase inhibitor will improve motor symptoms and functional status, but with an increase in dyskinesias. Deep brain stimulation is effective in patients who have poorly controlled symptoms despite optimal medical therapy. Occupational, physical, and speech therapy improve patient function. Fatigue, sleep disturbances, dementia, and depression are common in patients with Parkinson disease. Although these conditions are associated with significantly lower quality of life, they may improve with treatment.

[1]  Paul Crawford,et al.  Differentiation and diagnosis of tremor. , 2011, American family physician.

[2]  J. Patterson,et al.  Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland , 2009, Movement disorders : official journal of the Movement Disorder Society.

[3]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[4]  K. Sethi,et al.  A controlled trial of antidepressants in patients with Parkinson’s disease and depression , 2009, Current neurology and neuroscience reports.

[5]  C. Warren Olanow,et al.  The scientific and clinical basis for the treatment of Parkinson disease (2009) , 2009, Neurology.

[6]  D. Aarsland,et al.  Excessive daytime sleepiness in Parkinson disease , 2006, Neurology.

[7]  A. Hout,et al.  Dementia and survival in Parkinson disease , 2008, Neurology.

[8]  W. Weiner,et al.  Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) , 2006, Neurology.

[9]  H. Braak,et al.  A timeline for Parkinson's disease. , 2010, Parkinsonism & related disorders.

[10]  C. Ramaker,et al.  Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease. , 2007, The Cochrane database of systematic reviews.

[11]  W. Weiner,et al.  Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease , 2010, Neurology.

[12]  F. Horak,et al.  Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. , 2011, Archives of neurology.

[13]  E. Katunina,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[14]  H. Guchelaar,et al.  Glycopyrrolate for sialorrhea in Parkinson disease , 2010, Neurology.

[15]  C. Clarke,et al.  Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. , 2010, The Cochrane database of systematic reviews.

[16]  P. A. House,et al.  Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial , 2009 .

[17]  M. Mahowald,et al.  Rapid eye movement sleep parasomnias. , 2005, Neurologic clinics.

[18]  B. Mollenhauer,et al.  Associated factors for REM sleep behavior disorder in Parkinson disease , 2011, Neurology.

[19]  C. Counsell,et al.  Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. , 2009, The Cochrane database of systematic reviews.

[20]  Goutham Rao,et al.  Does this patient have Parkinson disease? , 2003, JAMA.

[21]  M. Hely,et al.  Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years , 2005, Movement disorders : official journal of the Movement Disorder Society.

[22]  W. Weiner,et al.  Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2006, Neurology.

[23]  J. Ferreira,et al.  Dopamine agonist therapy in early Parkinson's disease. , 2008, The Cochrane database of systematic reviews.

[24]  G. Deuschl,et al.  A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.

[25]  Shalini Jha,et al.  The diagnosis of Parkinson's disease. , 2003, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.

[26]  Albert Hofman,et al.  Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. , 2005, Archives of neurology.

[27]  S. Reich,et al.  The use of alternative therapies by patients with Parkinson’s disease , 2001, Neurology.

[28]  E. Montgomery Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2007, Neurology.

[29]  W. Poewe,et al.  Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2006, Neurology.

[30]  Y Ben-Shlomo,et al.  How valid is the clinical diagnosis of Parkinson's disease in the community? , 2002, Journal of neurology, neurosurgery, and psychiatry.

[31]  G. Logroscino,et al.  Parkinson disease and risk of mortality , 2008, Neurology.

[32]  A. E. Lang,et al.  Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review , 2002, Neurology.

[33]  S. Spieker,et al.  Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. , 2004, The Cochrane database of systematic reviews.

[34]  M. Hallett,et al.  Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2006, Neurology.

[35]  J. Friedman,et al.  Fatigue in levodopa-naïve subjects with Parkinson disease , 2008, Neurology.